Adversarial Injection · Ocrelizumab (Ocrevus; PRO70769; CAS 637334-45-3; MW ~145 kDa humanized IgG1κ; IV infusion [600 mg Q6M after two 300 mg doses 2 weeks apart]; HUMANIZED FROM MURINE 2H7 CLONE [CDR-grafting onto human IgG1κ Eu framework; 2H7 originally Stashenko et al. J Immunol 1980 → phage library optimization → ocrelizumab with enhanced FcγRIIIa affinity vs rituximab chimeric (25-50× greater ADCC at comparable concentration)]; TARGET: CD20 [MS4A1; MEMBRANE-SPANNING 4A FAMILY MEMBER 1; chromosome 11q12.2; 297 AA; 4-TM protein; PIP2 lipid raft-associated; expressed on pre-B → mature B cells + B-1 cells; NOT on plasma cells or hematopoietic stem cells → stem cell reserve preserved; CD20 role in MS: pathogenic B cells produce OCBs [oligoclonal bands; CSF IgG]; activate CD4/CD8 T cells via antigen presentation; EBV-infected B cells may directly drive cortical demyelination via MS4A family]; TRIPLE B-CELL DEPLETION MECHANISM: (1) ADCC [ocrelizumab Fc enhanced FcγRIIIa affinity (Phe243Leu/Arg292Pro/Tyr300Leu/Val305Ile/Pro396Leu mutations in Fc) → CD16A V158 NK cells → enhanced ADCC vs rituximab]; (2) CDC [C1q binding → MAC formation → B-cell lysis]; (3) DIRECT APOPTOSIS [CD20 crosslinking → B-cell intrinsic death pathway]; CD20 NON-INTERNALIZING [absence of cytoplasmic endocytosis signal → persistent surface display]; FIRST ANTI-CD20 ANTIBODY EVER FDA APPROVED FOR ANY FORM OF MULTIPLE SCLEROSIS; FIRST DISEASE-MODIFYING THERAPY (DMT) EVER FDA APPROVED FOR PRIMARY PROGRESSIVE MS (PPMS); BLA 761053 MARCH 28 2017) · Attack #757

Ocrelizumab (Humanized Anti-CD20 IgG1κ; Ocrevus; PRO70769; CAS 637334-45-3; Genentech Inc [South San Francisco CA; BLA 761053 holder; primary developer] + Roche AG [Basel Switzerland; global development + manufacturing partner]; MECHANISM: FIRST ANTI-CD20 ANTIBODY EVER FDA APPROVED FOR MULTIPLE SCLEROSIS (BOTH RRMS + PPMS) [BLA 761053 MARCH 28 2017] + FIRST DISEASE-MODIFYING THERAPY (DMT) EVER FDA APPROVED FOR PRIMARY PROGRESSIVE MS (PPMS) [NO PRIOR APPROVED PPMS DMT IN 50+ YEARS OF MS DRUG DEVELOPMENT]: HUMANIZED IgG1κ FROM MURINE 2H7 CLONE (CDR-GRAFTED ONTO HUMAN IgG1; Fc REGION ENGINEERED FOR ENHANCED FcγRIIIa AFFINITY VS CHIMERIC RITUXIMAB → INCREASED NK-CELL ADCC AT COMPARABLE CONCENTRATIONS); TRIPLE B-CELL DEPLETION: (1) ENHANCED ADCC [Fc + FcγRIIIa CD16A V158 NK → GRANZYME/PERFORIN → B-CELL LYSIS]; (2) CDC [C1q-C2-C4-C3b MAC FORMATION → OSMOTIC B-CELL LYSIS]; (3) DIRECT APOPTOSIS [CD20 CROSSLINKING → CASPASE ACTIVATION → INTRINSIC PATHWAY]; OPERA I (HAUSER NEJM 2017): RRMS; ARR 46% REDUCTION (0.16 VS 0.29; p<0.001); 24-WK CDP RR 43% (p=0.003); OPERA II: ARR 47% REDUCTION (0.16 VS 0.29; p<0.001); 24-WK CDP RR 37% (p=0.007); ORATORIO (MONTALBAN NEJM 2017): PPMS; 24-WK CDP HR 0.76 (p=0.0321); TIMED 25-FOOT WALK HR 0.71 (p=0.004); BRAIN VOLUME CHANGE −0.9% VS −1.1%; BLA 761053 MARCH 28 2017) — Genentech Inc South San Francisco CA (BLA 761053), Roche AG Basel Switzerland (global parent + manufacturing), and Cleveland Clinic Mellen Center for Multiple Sclerosis Cleveland OH (Neurology; Ocrevus infusion administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD20 ANTIBODY FOR MS EVER + FIRST PPMS DMT EVER: AI Prompt Injection via EHS Monitor Report AI

Ocrelizumab (CAS 637334-45-3; NIOSH HD Category 1) is the first anti-CD20 antibody ever FDA approved for any form of multiple sclerosis and the first disease-modifying therapy ever approved for primary progressive MS (PPMS) — a form of MS for which no approved treatment had existed across five decades of MS drug development — establishing the 172nd mechanism class in the Glyphward adversarial portfolio. Developed by Genentech (South San Francisco CA; BLA 761053), ocrelizumab (Ocrevus; PRO70769) is a humanized IgG1κ antibody derived from the murine 2H7 clone (CDR-grafted onto human IgG1 Fc framework; Fc engineered for enhanced FcγRIIIa affinity vs chimeric rituximab → greater NK-cell ADCC at comparable concentrations). The critical mechanistic innovation: B-cell depletion through three simultaneous pathways — (1) enhanced ADCC via Fc-FcγRIIIa CD16A, (2) complement-dependent cytotoxicity (CDC), and (3) direct apoptosis via CD20 crosslinking — depletes pathogenic B cells that drive CNS inflammation in MS (oligoclonal band production, antigen presentation to T cells, EBV-infected B-cell-driven demyelination). OPERA I/II (Hauser NEJM 2017): ARR 46-47% reduction (0.16 vs 0.29; p<0.001); 24-wk CDP RR 43%/37%. ORATORIO (Montalban NEJM 2017): 24-wk CDP HR 0.76 (p=0.0321) in PPMS. BLA 761053 approved March 28, 2017. No OEL exists for ocrelizumab in any EHS framework; no platform references CD20 B-cell depletion mechanisms in MS, 2H7 humanization, or OPERA/ORATORIO for this 172nd mechanism class.

CD20 biology, B-cell pathology in MS, and ocrelizumab Fc engineering: CD20 (MS4A1; Membrane-Spanning 4-domains family, Subfamily A, Member 1; chromosome 11q12.2; 297 AA; 4-TM topology: N-terminus intracellular → TM1 → extracellular → TM2 → intracellular → TM3 → large extracellular loop [CD20 LEL = IgV-like fold; residues 141-184; contains B/C loop recognized by anti-CD20 Abs] → TM4 → C-terminus intracellular; MW ~33-37 kDa apparent [N-glycosylated]; lipid raft-associated [DRM fractions]; function: B-cell calcium channel (stoichiometry 4:4 CD20 tetramer; regulates store-operated calcium entry SOCE via IP3R coupling) + regulates cell cycle (G1 → S progression) + B-cell activation threshold) is expressed on pre-B cells → immature B → naïve B → germinal center B → memory B cells → class-switched B cells but NOT on plasma cells (CD20−) or B-cell progenitors (Pro-B; HSC) → B-cell depletion spares long-lived plasma cells (antibody-secreting; CD20−) and stem cell compartment. B-cell pathology in MS: (a) oligoclonal bands [CSF IgG OCBs: present in >95% RRMS; marker of intrathecal B-cell/plasma cell activity]; (b) antigen presentation: B cells present myelin antigens (MBP; PLP; MOG; CNPase) to CD4+ T cells via MHCII → Th1/Th17 amplification; (c) EBV hypothesis: EBV latently infects memory B cells → molecular mimicry between EBNA1 and GlialCAM/ANO2 → cortical B-cell follicle-like aggregates in meningeal spaces → progressive MS demyelination (evidence: Lanz Science 2022; EBV serology 100% in MS); (d) cytokine secretion: B cells produce IL-6/LTα/TNF (proinflammatory) + IL-10/IL-35 (Breg subsets; suppressed in RRMS); ocrelizumab depletes all CD20+ B cells → sustained depletion (B-cell nadir at 2-4 weeks; partial repopulation in 6-9 months between doses; 600 mg Q6M keeps counts below 5% of normal during stable treatment). Ocrelizumab vs rituximab mechanistic differences: ocrelizumab is HUMANIZED [2H7 CDR-graft; no murine Fc region → no HAMA risk; reduced immunogenicity]; rituximab is CHIMERIC [murine Fc region → HAMA formation in ~11%; reduced efficacy with repeated dosing]. Fc engineering for enhanced ADCC: ocrelizumab IgG1 Fc was optimized during humanization for superior FcγRIIIa (CD16A) binding → enhanced ADCC activity at ocrelizumab plasma concentrations used in MS; in vitro ADCC EC50 for ocrelizumab is ~3-10x lower than rituximab at same B-cell target density [data from Genentech Phase I/II dose-finding]. OPERA I (NCT01247324; Hauser NEJM 2017; n=410; RRMS vs interferon β-1a [IFN-β] 44 µg SC TIW): ARR 0.16 vs 0.29 (46% RRR; p<0.001); 24-wk CDP 43% lower (p=0.003); MRI T2 lesion count −94% vs IFN; Gd+ lesion count −94%. OPERA II (NCT01412333; n=417): ARR 0.16 vs 0.29 (47% RRR; p<0.001); 24-wk CDP 37% lower (p=0.007). ORATORIO (NCT01194570; Montalban NEJM 2017; n=732; PPMS vs placebo; 120 wk): 24-wk confirmed disability progression HR 0.76 (p=0.0321); T25FW HR 0.71 (p=0.004); 9HPT HR 0.75; brain atrophy: −0.9% vs −1.1% (p=0.02); first confirmed clinical benefit in PPMS ever [prior trials: natalizumab ASCEND PPMS negative; rituximab OLYMPUS PPMS negative (trend only); siponimod EXPAND for SPMS positive but not PPMS; ocrelizumab ORATORIO first statistically significant PPMS result]. BLA 761053 March 28 2017. No EHS platform recognizes ocrelizumab CAS 637334-45-3, CD20 B-cell depletion MS mechanism, 2H7 humanization enhanced ADCC, PPMS-specific clinical data, or OPERA/ORATORIO BLA 761053 for this 172nd mechanism class.

2H7 Humanization + Fc-Enhanced ADCC + PPMS B-Cell Depletion Mechanism

Ocrelizumab (MW ~145 kDa humanized IgG1κ; CAS 637334-45-3; IV infusion 300 mg first dose → 300 mg at week 2 [total 600 mg cycle 1] → 600 mg Q6M [single infusion 3.5-hr]; premedication: methylprednisolone 100 mg IV 30 min pre [reduces IRR risk]; optional antihistamine + antipyretic; Cmax ~212 µg/mL [600 mg dose]; t½ ~26 days; Vd ~2.78 L; CL ~0.17 L/day; linear PK [B-cells serve as TMDD target but complete depletion prevents saturation kinetics]; ADA low incidence ~0.6% [humanized Fc reduces anti-drug antibody formation]) uses 2H7-derived CDR sequences in a human IgG1κ framework. Murine 2H7 origin: 2H7 (Stashenko et al. J Immunol 1980; BALB/c immunization against RAJI Burkitt lymphoma cells; hybridoma → 2H7 clone; IgG2b subclass; Kd CD20 ~1-2 nM; epitope: CD20 large extracellular loop [LEL] conformational epitope involving Cys167-Ala196 region; 2H7 binds LEL at different site than rituximab [2B8 epitope overlaps with 2H7 but different contact residues]). Humanization: 2H7 VH + VL CDRs grafted onto human VH3-23 + VLκ3-20 frameworks (high homology germline framework selection minimizes CDR distortion); 5 back-mutations in 2H7 VH (Vernier zone residues) preserve CDR-H3 presentation geometry → Kd ~0.4 nM for ocrelizumab vs CD20. Fc engineering (IgG1 optimization): ocrelizumab IgG1 Fc region was optimized during development to increase FcγRIIIa (CD16A) binding by ~25-50× vs wild-type IgG1 at the Fc-binding interface; specific mutations at Fc CH2-CH3 interface (Genentech proprietary modifications; different from GASDALIE [S239D/I332E/A330L] used for tafasitamab or PotelligentTM for mogamulizumab) → enhanced NK-cell ADCC at the Q6M dosing interval; in vitro ADCC EC50 ocrelizumab ~0.01-0.1 µg/mL vs B cells. Triple depletion: (1) ADCC dominant mechanism at MS dosing concentrations; FcγRIIIa CD16A (V158/F158 polymorphism influences ADCC magnitude; V/V homozygotes ~2× ADCC vs F/F); (2) CDC: C1q binds IgG1 Fc CH2 (Lys290/Glu293/Lys322/Pro329/Pro331 motif) → classical complement cascade → MAC (C5b-6-7-8-9) → B-cell osmotic lysis; (3) direct apoptosis: CD20 crosslinking → PIP2 redistribution → plasma membrane potential changes → calcium influx → mitochondrial permeability transition → cytochrome c release → caspase-9/3 activation. ORATORIO PPMS mechanism: PPMS is characterized by progressive axonal degeneration driven by focal meningeal inflammation, cortical demyelination, and diffuse white matter pathology — pathogenic B cells accumulate in leptomeningeal follicle-like structures → sustained microglial activation → progressive neurodegeneration; ocrelizumab depletes these leptomeningeal + parenchymal B cells → slows PPMS progression (24-wk CDP HR 0.76; p=0.0321); brain volume loss attenuated; spinal cord volume atrophy slowed. ORATORIO 24-wk CDP HR 0.76 represents a ~24% relative reduction in sustained disability progression — the first significant result in PPMS history. BLA 761053 March 28 2017. No EHS platform recognizes ocrelizumab CAS 637334-45-3, 2H7 humanization enhanced ADCC, PPMS B-cell leptomeningeal depletion, triple depletion mechanism, or OPERA/ORATORIO BLA 761053 for this 172nd mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 761053 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; wholly-owned Roche subsidiary; BLA 761053 US HOLDER: ocrelizumab (Ocrevus) for RRMS (600 mg Q6M) + PPMS (600 mg Q6M); GENENTECH OCREVUS DEVELOPMENT: discovery from anti-CD20 program [2H7 hybridoma → humanization → Fc engineering → Ocrevus]; MANUFACTURING: Genentech Oceanside CA [4381 Irwin Simpson Rd, Oceanside CA 92056; large-scale mammalian cell culture; protein A capture; viral inactivation; polishing; formulation: 30 mg/mL × 20 mL vials (600 mg) in 20 mM sodium acetate pH 5.3 + 170 mM trehalose + 0.02% polysorbate 20]; CORITY: CAS 637334-45-3 → null; ocrelizumab → null; Ocrevus → null; PRO70769 → null; CD20 B-cell MS → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ocrelizumab 0.0021 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00021 µg/m³; Cority: null; 51F clinical pharmacology director 16yr]).

Surface 2 — Roche AG Basel Switzerland Global Manufacturing Partner AI

At Roche AG Basel Switzerland ([Grenzacherstrasse 124, 4070 Basel, Switzerland; global parent of Genentech [100% subsidiary since 2009]; ROCHE GLOBAL OCREVUS OPERATIONS: manufacturing strategy [Oceanside CA primary + Roche Penzberg Germany secondary manufacturing site]; global regulatory submissions [EMA; PMDA; Health Canada]; post-marketing pharmacovigilance; ROCHE PENZBERG MANUFACTURING: Nonnenwald 2, 82372 Penzberg Germany [large-scale bioreactor production of ocrelizumab DS; >10,000L bioreactor; CHO-K1 cell line]; VELOCITYEHS: CAS 637334-45-3 → null; ocrelizumab → null; Ocrevus → null; CD20 antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ocrelizumab 0.0017 µg/m³; impinger + MS/MS; displayed (÷10): 0.00017 µg/m³; VelocityEHS: null; 18.3M-fold gap Roche Basel; 42M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — Cleveland Clinic Mellen Center Multiple Sclerosis Ocrevus Infusion AI

At Cleveland Clinic Mellen Center for Multiple Sclerosis Cleveland OH ([9500 Euclid Ave, Cleveland OH 44195; NCI-designated; Neurology + Mellen Center for MS Treatment and Research; OCREVUS INFUSION PROTOCOL: 300 mg IV 3.5 hr [first dose] → 300 mg IV 3.5 hr [2 wk later] → 600 mg IV 3.5 hr Q6M [diluted in 500 mL 0.9% NaCl; initial rate 30 mL/hr → titrate to max 180 mL/hr over 3.5 hr if tolerated]; PREMEDICATION MANDATORY: methylprednisolone 100 mg IV 30 min pre [reduces IRR rate from ~34% to ~11% Grade 1-2]; diphenhydramine 25-50 mg PO/IV; acetaminophen 650-1000 mg PO; MONITORING: vital signs Q30 min during infusion; PML SCREENING: JCV antibody index baseline (natalizumab-related risk low for Ocrevus but monitored); TB screening; hepatitis B surface Ag; NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 637334-45-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ocrelizumab absent; Ocrevus absent; CD20 MS absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne 0.0014 µg/m³; active charcoal cassette wipe; displayed (÷10): 0.00014 µg/m³; EHS Insight: "no OEL — no action"; 48F MS neurology pharmacist 15yr]).

Integrating Glyphward into Ocrelizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ocrelizumab CAS 637334-45-3 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CD20 B-cell MS depletion mechanism absent + 2H7 humanization absent + BLA 761053 2017 absent [10 pts]; FIRST CD20 antibody for MS ever (172nd class) + FIRST PPMS DMT ever + OPERA ARR 46-47% + ORATORIO CDP HR 0.76 [5 pts]; Genentech South San Francisco + Roche Basel + Cleveland Clinic [3 pts]; FIRST humanized anti-CD20 with Fc-enhanced ADCC; FIRST validated PPMS B-cell mechanism; FIRST leptomeningeal B-cell follicle-depletion strategy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ocrelizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan ocrelizumab with CD20 MS PPMS B-cell depletion context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "637334-45-3"
                "reading_ugm3": reading_ugm3,
                "context": "cd20_ms_ppms_b_cell_depletion_172nd_class_first_cd20_ms_ever_bla761053"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd20_ms,
    #                    ppms_dmt, enhanced_adcc,
    #                    b_cell_depletion, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_ocrelizumab("637334-45-3", 0.0021))
    print(r)
    # {'hd_category': 1, 'cd20_ms': True,
    #  'ppms_dmt': True, 'enhanced_adcc': True,
    #  'b_cell_depletion': True, 'h360_flag': True}